

RESEARCH

Open Access



Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen

Yi-Hsuan Lin⁵, Chia-Hung Lin^{1,2}, Yu-Yao Huang^{1,3}, Hsin-Yun Chen¹, An-Shun Tai⁴, Shih-Chen Fu⁴, Sheng-Hwu Hsieh¹, Jui-Hung Sun¹, Szu-Tah Chen¹ and Sheng-Hsuan Lin^{4*}

Abstract

Background Increasing evidence suggests that glucagon-like peptide 1 (GLP-1) receptor agonists (RA) can stabilize glycemic variability (GV) and interfere with eating behavior. This study compared the impact of insulin, GLP-1 RA, and dietary components on GV using professional continuous glucose monitoring (CGM).

Methods Patients with type 2 diabetes underwent CGM before and after switching from a twice-daily pre-mixed insulin treatment regimen to a GLP-1 RA (liraglutide) plus basal insulin regimen. The dietary components were recorded and analyzed by a certified dietitian. The interactions between the medical regimen, GV indices, and nutrient components were analyzed.

Results Sixteen patients with type 2 diabetes were enrolled in this study. No significant differences in the diet components and total calorie intake between the two regimens were found. Under the pre-mixed insulin regimen, for increase in carbohydrate intake ratio, mean amplitude of glucose excursion (MAGE) and standard deviation (SD) increased; in contrast, under the new regimen, for increase in fat intake ratio, MAGE and SD decreased, while when the protein intake ratio increased, the coefficient of variation (CV) decreased. The impact of the food intake ratio on GV indices disappeared under the GLP-1 RA regimen. After switching to the GLP-1 RA regimen, the median MAGE, SD, and CV values decreased significantly. However, the significant difference in GV between the two regimens decreased during the daytime.

Conclusion A GLP-1 RA plus basal insulin regimen can stabilize GV better than a regimen of twice-daily pre-mixed insulin, especially in the daytime, and can diminish the effect of food components on GV.

Keywords Continuous glucose monitoring, Glucose variability, Pre-mixed insulin, GLP-1 receptor agonist, Diet

*Correspondence:

Sheng-Hsuan Lin

shenglin@stat.nctu.edu.tw

Full list of author information is available at the end of the article



© The Author(s) 2022, corrected publication 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

In patients with diabetes mellitus, the target of blood sugar control is to maintain the mean glucose level, which is presented as glycated hemoglobin A1c (HbA1c) along with the glycemic variability (GV) [1]. High GV increases oxidative stress and inflammation [2, 3], which could be the possible etiologies of cardiovascular complications in diabetes mellitus [4]. Owing to technological advancements, the continuous glucose monitoring (CGM) system can evaluate the glucose level in the interstitial fluid, which is representative of the blood glucose level [5]. Furthermore, by evaluating the fluctuation in glucose levels and calculating the GV indices, physicians can adjust medication in time and further improve patient outcomes [6, 7]. Food intake plays an important role in GV. In both type 1 and type 2 diabetes, a low carbohydrate diet for 3 months can decrease GV and antidiabetic medication requirement [8, 9]. Further, the carbohydrate (CHO), protein (PRO), and fat intake have an impact on glucose control and cardiovascular risk factors in patients with diabetes mellitus [10].

Various categories of antidiabetic drugs are being used, and as a new class of antidiabetic agents, namely, glucagon-like peptide 1 (GLP-1) receptor agonists (RA), can decrease appetite and body weight and increase insulin sensitivity. In addition, GLP-1 RA provides cardiovascular protection [11, 12]. Bajaj et al. showed that long-acting GLP-1 RA combined with basal insulin had a lower GV than basal-bolus insulin, pre-mixed insulin, or basal-bolus insulin combined with oral drugs [13]. However, insulin is the cornerstone of glucose control, especially in patients with type 2 diabetes and beta-cell function failure [14]. However, use of insulin increases the risk of hypoglycemia [13].

Although several studies on GLP-1 RA exist, no research has investigated the effect of GLP-1 RA on diet components and GV compared with that of the pre-mixed insulin regimen in the same patients.

Therefore, to evaluate the interaction between GV, food intake, and diabetes mellitus treatment regimen, we enrolled 16 patients with type 2 diabetes who were under a pre-mixed insulin regimen and applied the first CGM. Additionally, the diet components were recorded. We then changed the treatment regimen to GLP-1 RA combined with basal insulin and applied a second CGM. We compared GV and dietary components before and after the treatment shift. This pilot study aimed to analyze the effects of insulin and GLP-1 RA on GV and food intake.

Methods

Participants

Sixteen patients (eight females and eight males) with type 2 diabetes who were treated with pre-mixed insulin

combined with other oral antidiabetic drugs (OADs) were enrolled. Patients who were independent and cooperated to receive CGM and recorded their diet log by themselves or with the help of a family member were included. They received their first CGM at baseline. We then calculated the dose of insulin to be basal insulin in the pre-mixed insulin regimen and then shifted to insulin glargine U300 with the same dose combined with liraglutide, and titrated or tapered the doses according to the patients' response. The second CGM was performed three months later after shifting to basal insulin (insulin glargine U300) combined with a GLP-1 RA (liraglutide) regimen when the patients' sugar levels were relatively stable. Eleven patients were injected with liraglutide in the morning and five patients were injected in the evening, and all patients received insulin glargine U300 in the morning.

Physical activity and dietary habits were the patients' routines. The exclusion criteria were (a) presence of any severe cardiovascular disorder, (b) history of influenza infection, (c) autoimmune disease or metabolic disorders, (d) drug or alcohol abuse, and (e) participation in another clinical investigation study. The medical records of all participants were retrospectively reviewed. This study was approved by the Institutional Review Board (IRB) and the ethics committee of Chang Gung Memorial Hospital (CGMH) (IRB No. 201701492B0). The IRB waived the requirement for obtaining informed consent, as this study was retrospective and the decision making of clinical physicians was not interfered with, at that time. The confidentiality of the research subjects was maintained according to the requirements of the IRB of CGMH (Taipei, Taiwan).

Diet records

The participants and their family members were educated on how to record the components of all the food items they consumed by a certified dietitian. The amount and type of food, fruits, snacks, beverages, and desserts, and the method of preparation was recorded. The details of nutrient elements, including the weight and calories of CHO, PRO, and fats, were analyzed by the dietitian after CGM completion, and the ratio of calories from each element to the total daily calories was calculated. We included diet analysis results on the days in which the patients had an intact 24-h CGM record.

Glucose monitoring

CGM was conducted using iPro™2 Professional CGM (Medtronic, Inc., Northridge, CA, USA). The CGM sensor needle was pierced into the subcutaneous tissue of the abdomen, buttocks, or arms of the participants. All patients underwent 24-h monitoring for approximately

6 d at home and we included data on the days in which the patients had intact 24-h CGM record. The sensor detects the glucose level in the interstitial fluid every 10 s and outputs an average value every 5 min. A time lag for glucose level change in the interstitial fluid existed as diffusion of glucose from the serum to the interstitial space takes time [15]. Therefore, patients were required to input capillary blood sugar levels four times a day to correct the output value. CGM could recognize interstitial fluid glucose levels from 40 to 400 mg/dL. If the values were out of this range, the CGM output value would be 40 or 400 mg/dL.

The HbA1c level was measured within 3 months before CGM and again after the first and second CGM.

Glucose variability indices measures

The collected data were downloaded using CareLink™ iPro software (Medtronic, Inc., Northridge, CA, USA) after the completion of this study. Several parameters were used to demonstrate the GV level, including standard deviation (SD) [16], percentage coefficient of variation (%CV) [16], and mean amplitude of glucose excursion (MAGE) [16]. The time spent with glucose levels within 70–180 mg/dL was considered the time in range (TIR), which was approximately half the self-monitoring of blood glucose (SMBG) recorded within this range. Thus, the HbA1c level was approximately 7% [17]. The HbA1c level can be expressed as a percentage, which means that the proportion of the glucose level within this range accounts for the total reading time. The area under the curve (AUC) of glucose levels >180 mg/dL (AUC₁₈₀) and <70 mg/dL (AUC₇₀) was represented as hyperglycemic and hypoglycemic periods, respectively. AUC_t and AUC_n represent the total and normal (70–180 mg/dL) AUCs for glucose levels, respectively [18]. The low blood glucose index (LBGI) and high blood glucose index (HBGI) were calculated based on glucose levels and represented the risk of hypoglycemia and hyperglycemia, respectively [19]. The M-value was calculated to evaluate GV [19]. Continuous overlapping net glycemic action (CONGA) was used as an indicator for the evaluation of blood glucose fluctuations in a relatively short period. It assesses intraday GV at different set intervals [19]. For instance, CONGA₄ represents the standard deviation of the blood glucose level every 4 h compared to that recorded at the previous interval.

Statistical analysis

All statistical analyses were performed using Statistical Analyses Package Program SPSS Statistics for Windows (version 26.0; SPSS, Inc., Chicago, IL, USA). Differences in continuous variables between the two regimens were calculated using the Wilcoxon signed-rank test. Nominal

variables were analyzed using the McNemar's Chi-square test. A linear mixed model was used for the two continuous variants to predict the response of a single variable. The relationship between two variables was measured to determine the strength of each variable using Spearman's correlation coefficient. Statistical significance was set at $p < 0.05$.

Results

All patients completed CGM under pre-mixed insulin and GLP-1 RA plus basal insulin regimens. The average interval between the first and second CGM was 67.5 d. All participants were aged between 44.2 and 85.5 years, and the average duration of diabetes mellitus was 10.8 years. The demographic characteristics of all participants are summarized in Table 1. The most frequently combined OAD with a pre-mixed insulin regimen and GLP-1 RA was metformin (56.3% and 68.8%, respectively).

Participants required higher total daily insulin doses and more basal insulin doses under the pre-mixed insulin regimen than under the GLP-1 RA combined with basal insulin regimen. The total daily median insulin dose was 50 U in the pre-mixed insulin regimen and 25 U in the GLP-1 RA combined with basal insulin regimen. The basal insulin dose used was higher in the pre-mixed insulin regimen. Regarding nutrient composition, although no statistical significance was found, participants consumed more calories under the pre-mixed insulin regimen than under the GLP-1 RA combined with basal insulin regimen. With regard to nutrient ingredients, no difference in CHO, PRO, and fat intake ratios between the two regimens was found.

Whole-day SD, CV, MAGE, CONGA₂, and CONGA₄ levels were lower in the GLP-1 RA combined with basal insulin regimen than in the pre-mixed insulin regimen. However, no difference in nocturnal glucose variability indices between the two regimens was found (Table 2). Under the pre-mixed insulin regimen, for every 1% increase in calorie ratio of CHO intake, MAGE and SD increased by 2.699 mg/dL and 1.324 mg/dL, respectively. For every 1% increase in calorie ratio of fat intake, MAGE and SD decreased by 3.487 mg/dL and 1.595 mg/dL, respectively. For every 1% increase in calorie ratio of PRO intake, CV decreased by 0.021% (Table 3). Briefly, increased CHO intake ratio was moderately and positively correlated with increased SD and CV ($r = 0.366$ and 0.420 , respectively, $p < 0.05$). However, increased PRO and fat intake ratios moderately and negatively correlated with reduced CV ($r = -0.423$ and -0.363 , respectively; $p < 0.05$). Moreover, MAGE, SD, and CV had a moderate positive correlation with age and the duration of diabetes mellitus (Additional file 1: Table S1).

Table 1 Demographic and diet characteristics of participants

	Pre-mix insulin regimen (n = 16)	GLP-1 RA added on basal insulin regimen (n = 16)	p
Age (y)	59.8 [50.3, 70.1]	–	–
Sex, male (n,%)	8(50)	–	–
Body weight (kg)	71.5 [61.8, 84.5]	71.5 [61.8, 84.5]	0.500
Height (cm)	164.8 [150.5, 169.8]	–	–
BMI (kg/m ²)	27.0 [25.0, 30.9]	–	–
Duration of disease (y)	10 [6, 14.5]	–	–
HbA1c (% , mmol/mol) before CGM	9.5 [8.7, 10.9] 80.3 [71.6, 95.6]	9.4 [8.3, 9.9] 78.7 [67.5, 85.0]	0.099
HbA1c (% , mmol/mol) after CGM	9.4 [8.3, 9.9] 78.7 [67.5, 85.0]	9.0 [7.8, 10.1] 74.9 [61.5, 86.6]	0.767
Difference of HbA1c (% , mmol/mol) before and after CGM	– 0.7 [– 1.4, 0.2] – 7.7 [– 15.3, 2.2]	0 [– 0.3, 0.3] 0 [– 3.3, 3.0]	0.125
Total daily insulin dose (U)	50.0 [45.3, 55.8]	25.0 [21.0, 33.0]	<0.001 ^a
Total daily insulin dose/BW (U/kg)	0.61 [0.52, 0.82]	0.36 [0.27, 0.43]	<0.001 ^a
Basal daily insulin dose (U)	35.0 [30.4, 38.9]	25.0 [21.0, 33.0]	0.001 ^a
Bolus daily insulin dose(U)	14.5 [13.1, 16.4]	0.0 [0.0, 0.0]	<0.001 ^a
Combined with OAD type			
Metformin (N, %)	9 (56.3)	11(68.8)	0.424
Sitagliptin (N, %)	4 (25)	0 (0)	0.012 ^a
Dapagliflozin (N, %)	1 (6.3)	0 (0)	<0.001 ^a
Acarbose (N, %)	2 (12.5)	2 (12.5)	0.004 ^a
Pioglitazone (N, %)	0 (0)	1 (6.3)	<0.001 ^a
Glimepiride (N, %)	0 (0)	1 (6.3)	<0.001 ^a
Nutrient composition (per day)			
CHO (%)	50.5 [46.0, 54.8]	50.5 [42.0, 53.8]	0.605
CHO (g)	158.4 [143.0, 175.6]	143.3 [118.6, 168.3]	0.163
PRO (%)	14.7 [13.1, 16.0]	15.1 [13.6, 18.0]	0.148
PRO (g)	48.4 [34.4, 60.7]	41.5 [32.2, 58.0]	0.569
Fat (%)	34.6 [32.1, 38.4]	35.7 [31.6, 40.0]	0.717
Fat (g)	48.9 [36.7, 64.1]	45.3 [30.4, 63.3]	0.289
Average calories per day (kcal)	1228.0 [1038.6, 1499.5]	1231.0 [879.5, 1412.6]	0.179
Calories/ body weight (kcal/kg)	16.6 [14.1, 21.3]	17.0 [12.6, 19.9]	0.215
Carbohydrate (g) / body weight (kg)	2.01 [1.88, 2.56]	2.05 [1.58, 2.39]	0.215
PRO (g) / body weight (kg)	0.58 [0.53, 0.86]	0.61 [0.55, 0.79]	0.796
Fat (g) / body weight (kg)	0.68 [0.53, 0.88]	0.65 [0.43, 0.80]	0.469

Age, body weight, height, body mass index, duration of disease, HbA1c before/after CGM, insulin dose, and nutrient composition are presented as the median [Q1, Q3]. Continuous variants were analyzed by Wilcoxon signed-rank test and nominal variants were analyzed by McNemar's Chi-square test

GLP-1 RA Glucagon-like peptide 1 receptor agonist; BMI Body mass index; HbA1c Glycated hemoglobin A1c CGM Continuous glucose monitoring; OAD Oral antidiabetic drug; CHO Carbohydrate; PRO Protein

^aa denotes p value < 0.05"

After the participants switched from a pre-mixed insulin regimen to a GLP-1 RA combined with basal insulin regimen, the median MAGE, SD, and CV decreased significantly from 114.2 to 78.7 mg/dL, from 43.9 to 36.0 mg/dL, and from 0.24 to 0.20%, respectively (Table 2 and Fig. 1). However, the impact of food intake on GV was only observed during the daytime. No significant reduction in nocturnal MAGE, SD, or CV was found

(Fig. 2). Although not statistically significant, the TIR ratio increased from 45.1 to 52.9% after the participants changed to the GLP-1 RA combined with basal insulin regimen (Fig. 3). The correlation between the calorie ratio of CHO and TIR was – 0.224 and – 0.044 in the pre-mixed insulin regimen and basal insulin plus GLP-1 RA regimen, respectively. The results were not statistically significant. The time course of the mean blood glucose

Table 2 Results of computerized glycemic variability index

	Pre-mix insulin usage (N = 16)	GLP-1 agonist added on basal insulin usage (n = 16)	p
All day period (0:00–24:00)			
SD	43.9 [34.4, 60.6]	36.0 [27.7, 47.5]	0.017 ^a
CV	0.24 [0.21, 0.29]	0.20 [0.15, 0.26]	0.046 ^a
MAGE	114.2 [91.4, 151.4]	78.7 [66.8, 124.8]	0.006 ^a
AUCt	50869.2 [44430.2, 66563.7]	53484.3 [41642.7, 59404.7]	0.918
AUC180	31850.4 [15978.1, 55968.9]	34434.3 [12336.0, 46503.3]	0.535
AUCn	18672.2 [9534.4, 28527.5]	19419.5 [13836.7, 28965.2]	0.408
AUC70	0.0 [0.0, 175.0]	0.0 [0.0, 0.0]	0.674
LBG1	0.07 [0.00, 0.41]	0.00 [0.00, 0.18]	0.463
HBG1	9.68 [5.41, 20.28]	9.46 [4.14, 14.48]	0.535
M-value	23.47 [13.12, 45.15]	18.45 [10.49, 27.86]	0.088
CONGA1	28.07 [23.33, 39.29]	23.25 [19.93, 34.58]	0.079
CONGA2	42.80 [35.88, 56.29]	36.45 [31.46, 54.49]	0.049 ^a
CONGA4	56.94 [45.81, 70.33]	50.49 [38.80, 62.95]	0.020 ^a
TIR	39.0 [24.1, 71.7]	52.6 [31.4, 77.6]	0.305
Duration above upper limit (%)	61.0 [27.0, 76.0]	47.4 [19.9, 68.6]	0.352
Duration within limits (%)	39.0 [24.1, 71.7]	52.6 [31.4, 77.6]	0.453
Duration below lower limit (%)	0.0 [0.0, 0.6]	0.0 [0.0, 0.0]	0.624
Nocturnal period (00:00–06:00)			
SD	14.8 [9.3, 20.2]	11.5 [9.39, 19.9]	0.605
CV	0.09 [0.08, 0.13]	0.07 [0.06, 0.13]	0.796
MAGE	34.9 [23.1, 50.4]	32.9 [25.1, 60.0]	0.642
AUCt	11771.3 [8691.5, 14551.0]	11015.0 [8383.6, 12973.3]	0.569
AUC180	3822.2 [260.1, 12524.9]	2262.3 [13.6, 6654.3]	0.363
AUCn	6176.7 [2794.0, 8419.7]	7392.8 [5662.3, 8730.4]	0.278
AUC70	0.0 [0.0, 0.0]	0.0 [0.0, 0.0]	0.715
LBG1	0.09 [0.00, 0.59]	0.00 [0.00, 0.51]	0.552
HBG1	6.24 [1.32, 14.17]	4.31 [0.86, 8.44]	0.379
M-value	8.96 [5.01, 22.66]	7.71 [3.32, 15.82]	0.408
CONGA1	13.20 [9.52, 16.57]	10.61 [8.53, 13.21]	0.438
CONGA2	14.12 [11.61, 19.84]	12.58 [10.17, 16.80]	0.234
CONGA4	11.64 [9.15, 13.36]	9.87 [8.08, 14.26]	0.642

Each glycemic variability index is presented as the median [Q1, Q3]. Continuous variants were analyzed by Wilcoxon signed-rank test

SD standard deviation; CV coefficient of variation; MAGE mean amplitude of glycemic excursions; AUC area under curve; LBG1 low blood glucose index; HBGI high blood glucose index; M-value weighted average of glucose value; CONGA continuous overlapping net glycemic action; TIR time in range

^a denotes p value < 0.05

variations in individual subjects in the two groups is shown in Fig. 4.

Discussion

The current pilot study analyzed the correlation between diet components, GV, and antidiabetic regimens of pre-mixed insulin or GLP-1 RA plus basal insulin using CGM and diet records.

GLP-1 RA can reportedly improve blood glucose control by increasing insulin secretion and insulin sensitivity and decreasing appetite and body weight [20].

However, insulin is the most effective blood glucose-lowering agent. Therefore, for patients with hyperglycemic urgency or very poorly controlled diabetes mellitus, insulin is the first-line therapy [21], although it increases the risk of hypoglycemia. Insulin is a regulator of appetite [22] and can decrease appetite. However, their physiological metabolism leads to increased body weight [23, 24], which, in turn, leads to higher GV [25].

Liraglutide, a once-daily GLP-1 RA, was approved for use as an antidiabetic and body weight control medication by the US Food and Drug Administration [26]. The

Table 3 Impact of nutrient components on MAGE, SD and CV

Parameter	MAGE (mg/dl)								
	Total person times (n = 32)			Pre-mix insulin regimen (n = 16)			GLP-1 RA on basal insulin regimen (n = 16)		
Variable	β	95% CI of β	P	β	95% CI of β	p	β	95% CI of β	p
CHO (%)	1.141	(- 0.481,2.763)	0.168	2.699	(0.067,5.332)	0.045 ^a	0.918	(- 1.567, 3.404)	0.441
Pro (%)	- 6.494	(- 12.124,-0.865)	0.023 ^a	- 3.462	(- 14.797,7.873)	0.523	- 2.267	(- 11.893, 7.358)	0.621
Fat (%)	- 1.092	(- 3.013, 0.827)	0.264	- 3.487	(- 6.529,-0.446)	0.028 ^a	- 1.076	(- 4.028, 1.876)	0.448
CHO (gram/kg)	14.80	(- 11.941,41.546)	0.278	16.77	(- 28.008,61.556)	0.435	11.49	(- 30.454,53.428)	0.566
Pro (gram/kg)	- 51.39	(- 123.139,20.357)	0.160	- 47.77	(- 159.053,63.518)	0.373	- 18.49	(- 123.15,86.172)	0.711
Fat (gram/kg)	- 26.80	(- 82.136,28.523)	0.342	- 67.82	(- 146.583,10.939)	0.086	- 23.13	(- 107.945, 61.689)	0.568
Parameter	SD (mg/dl)								
CHO (%)	0.440	(- 0.165,1.045)	0.154	1.324	(0.409,2.239)	0.008 ^a	0.266	(- 0.704,1.235)	0.566
PRO (%)	- 2.768	(- 4.786,-0.750)	0.007 ^v	- 2.854	(- 7.023,1.315)	0.164	- 1.155	(- 4.849,2.539)	0.513
Fat (%)	- 0.369	(- 1.085,0.347)	0.312	- 1.595	(- 2.677-0.513)	0.007 ^a	- 0.263	(- 1.419,0.892)	0.632
CHO (gram/kg)	4.874	(- 5.153,14.901)	0.340	8.475	(- 8.677,25.627)	0.307	4.403	(- 11.806,20.612)	0.570
PRO (gram/kg)	- 17.00	(- 44.015,10.019)	0.217	- 21.63	(- 64.482,21.213)	0.297	- 3.635	(- 44.228,36.959)	0.851
Fat (gram/kg)	- 5.428	(- 26.362,15.469)	0.610	- 25.17	(- 56.163,5.821)	0.103	- 4.297	(- 37.377,28.782)	0.785
Parameter	CV (%)								
CHO (%)	0.003	(0.0007,0.006)	0.011 ^a	0.004	(0,0.009)	0.061	0.003	(- 0.001,0.006)	0.120
PRO (%)	- 0.013	(- 0.023,-0.003)	0.013 ^a	- 0.021	(- 0.036,-0.006)	0.009 ^a	- 0.004	(- 0.019,0.011)	0.566
Fat (%)	- 0.004	(- 0.007,-0.0002)	0.032 ^a	- 0.004	(- 0.01,0.002)	0.158	- 0.004	(- 0.008,0.001)	0.095
CHO (gram/kg)	0.006	(- 0.041,0.052)	0.806	0.001	(- 0.075,0.078)	0.971	- 0.002	(- 0.593,0.553)	0.941
PRO (gram/kg)	- 0.134	(- 0.243,-0.025)	0.016 ^a	- 0.187	(- 0.346,-0.029)	0.023 ^a	- 0.1	(- 0.254,0.054)	0.186
Fat (gram/kg)	- 0.097	(- 0.182,-0.012)	0.025 ^a	- 0.113	(- 0.245,0.018)	0.085	- 0.105	(- 0.225,0.014)	0.080

Linear mixed model analysis with β as standardized coefficient

MAGE mean amplitude of glycemic excursions; SD standard deviation; CV coefficient of variation; CHO carbohydrate; PRO protein

^a denotes p value < 0.05




Fig. 1 Changes in **A** MAGE **B** CV **C** SD from the pre-mixed insulin regimen to the GLP-1 RA combined with basal insulin regimen. The data are presented as median [Q1, Q3]

drug helps in delaying gastric emptying and suppresses appetite by inhibiting the neuronal pathway. In addition, the drug controls blood sugar by increasing insulin secretion and insulin sensitivity and decreasing hepatic glucose production [27]. In contrast, central administration of insulin inhibits appetite and causes weight loss

[22]. However, insulin therapy in diabetes causes body weight and fat mass gain owing to its anabolic effect and dietary compensation for hypoglycemia [28, 29]. In this study, no statistically significant difference was found in the nutrient components and total calorie intake every day between the two regimens, but a lower daily calorie




Fig. 2 Changes in daytime and nocturnal **A** MAGE **B** CV **C** SD from the pre-mixed insulin regimen to the GLP-1 receptor agonist combined with basal insulin regimen. The data are presented as median [Q1, Q3]

intake was observed under the pre-mixed insulin regimen; however, evaluating significance of the difference is difficult, owing to the small sample size. In addition,

insulin has an anorexic effect, although central insulin resistance may decrease appetite [29]. Liraglutide with basal insulin regimen was associated with decreased




Fig. 3 Changes in the time spent (%) in glucose ranges from the pre-mixed insulin regimen to the GLP-1 RA combined with basal insulin regimen

total daily insulin dose and basal insulin dose (from 35 to 25 median units basal insulin, $p < 0.001$ for both) compared with the pre-mixed insulin regimen. Carris et al. reviewed several studies and showed that liraglutide combined with basal insulin can reduce the basal insulin dose, body weight, and risk of hypoglycemia [29]. Adjustments in OAD were made after switching to basal insulin combined with the GLP-1 RA regimen. Given the limitations of the drug mechanism (both incretin-based therapy with DPP-4 inhibitors and GLP-1 RA) and health insurance in Taiwan (cannot use GLP-1 RA and SGLT2 inhibitor simultaneously), the OAD must be adjusted while shifting regimens. However, the results

still represent real-world conditions and provide suggestions for clinical physicians.

Nutrient components were found to interfere with GV, especially during the pre-mixed insulin regimen. An increase in CHO intake ratio increased GV, whereas an increase in PRO and fat intake ratios decreased GV. Only a few studies have analyzed the correlation between nutrients and GV. Tay et al. showed that, in patients with type 2 diabetes, a low-CHO diet can reduce CONGA₁ and diabetes medication requirements compared with a high-CHO diet [9]. Thomsen et al. tried to replace the conventional diabetes mellitus diet with a CHO-reduced high-PRO diet and showed a 36–45% reduction in GV indices [30]. Moreover, previous studies have demonstrated that the higher the PRO percentage intake, the lower the MAGE level [31]. Mori et al. further demonstrated that a low-CHO and high-monounsaturated fatty acid liquid diet could stabilize GV and reduce HbA1c levels compared to a high-CHO liquid diet [32]. Furthermore, SD is reportedly lower with the basal insulin plus GLP-1 RA (exenatide or liraglutide) regimen than with the pre-mixed insulin regimen [13], consistent with the findings of the present study. Moreover, when combined with basal insulin or with multiple daily insulin injections, liraglutide could increase TIR, regardless of daytime or nighttime [33]. In contrast, even when not combined with GLP-1 RA, basal insulin can decrease GV in comparison to pre-mixed insulin [34]. Taken together, macro-nutritional components interfere with GV, and




Fig. 4 Time course of mean blood glucose variations in individual subjects. **A** Participants treated with the pre-mixed insulin regimen and **B** participants treated with the GLP-1 RA combined with basal insulin regimen. The data are presented as mean ± 95% confidence intervals

both GLP-1 RA and basal insulin can lead to a decline in GV.

Both age and duration of diabetes mellitus had a moderately negative correlation with MAGE, CV, and SD, indicating that the longer the duration of diabetes mellitus and the older the patient, the higher the GV index. This result is consistent with those of many previous reports. Tong et al. showed that patients with type 2 diabetes and HbA1c levels > 7% had longer diabetes duration and higher GV indices [35]. Furthermore, Gude et al. [36] noted an increase in GV indices with age. In the Diabetes Outcomes in Veterans Study, 204 patients with type 2 diabetes receiving insulin treatment were included and underwent 8-week self-monitoring of blood glucose levels. The follow-up results showed that older participants and those with a longer duration of insulin treatment had higher GV [37]. However, Noyes et al. reported the opposite finding in a case–control study involving 10,130 participants with type 2 diabetes; the group revealed that younger participants had higher HbA1c variability [38]. Because of the short-term but exact measurement by CGM, HbA1c variability had a different presentation of mean glucose variability over a longer period.

This pilot study, however, had several limitations. First, this study had a relatively small sample size. Second, the interval between the two CGM periods was not long enough to observe a changing trend in HbA1c levels. Third, no intervention was involved for the participants' daily physical activity. Thus, the impact of exercise could not be estimated. Fourth, the glycemic index of food was not calculated. Fifth, although beta-cell failure can diminish the glycemic effect of GLP1-RA, data on c-peptide levels in this study were incomplete given that this study was retrospective and that c-peptide levels were not routinely examined. However, this study could serve as a pilot for future studies on new and improved antidiabetic regimens.

Conclusions

In conclusion, GLP-1 RA, in combination with basal insulin, regimen can better stabilize GV than a twice-daily pre-mixed insulin regimen, especially in the daytime, although no significant impact on the consumption of macro-nutrition and calories was found.

Abbreviations

HbA1c	Glycated hemoglobin A1c
GV	Glycemic variability
CGM	Continuous glucose monitoring
CHO	Carbohydrate
PRO	Protein
GLP-1	Glucagon-like peptide 1
RA	Receptor agonists
OAD	Oral antidiabetic drugs
CGMH	Chang Gung Memorial Hospital
SD	Standard deviation

CV	Coefficient of variation
MAGE	Mean amplitude of glucose excursion
TIR	Time in range
SMBG	Self-monitoring of blood glucose
AUC	Area under the curve
LBGI	Low blood glucose index
HBGI	High blood glucose index
CONGA	Continuous overlapping net glycemic action

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40001-022-00892-9>.

Additional file 1: Table S1. Correlation of MAGE, SD, CV and Age, BMI, diabetes duration, HbA1c value before CGM study, percentages of carbohydrate, protein, and fat intake per day.

Author contributions

Yi-Hsuan Lin wrote the manuscript and collected and analyzed data; Chia-Hung Lin reviewed the manuscript; Yu-Yao Huang researched data; Hsin-Yun Chen analyzed diet data; An-Shun Tai analyzed statistical data; Shih-Chen Fu analyzed statistical data; Sheng-Hwu Hsieh collected data; Jui-Hung Sun collected data; Szu-Tah Chen researched data; and Sheng-Hsuan Lin reviewed and edited the manuscript. All the authors were involved in data interpretation, critical revision, and approval of the manuscript. Sheng-Hsuan Lin is the guarantor of this work and has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Funding

This research was supported by grants from the Ministry of Science and Technology, ROC (MOST 105–2628-B-182A-007-MY3, MOST 109–2314-B-182–049-MY3, and 109–2636-B-009–001) and Chang Gung Memorial Hospital (CMRPG5F0081, CMRPG3H0401, CMRPG3H0402, CMRPG3H0403, CMRPG3H0941, CMRPG3H0942, CMRPG3H0943, and CORPG5F0011).

Availability of data and materials

Not applicable.

Declarations

Ethical approval and consent to participate

This study was approved by the Institutional Review Board (IRB) and the ethics committee of Chang Gung Memorial Hospital (CGMH) (IRB No. 201701492B0). The IRB waived the requirement for informed consent. The confidentiality of the research subjects was maintained according to the requirements of the IRB of CGMH (Taipei, Taiwan).

Competing interests

The authors declare no conflict of interest.

Author details

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan. ²Department of Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. ³Department of Medical Nutrition Therapy, Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan. ⁴Institute of Statistics, National Chiao Tung University, Hsinchu, Taiwan. ⁵Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.

Received: 30 September 2022 Accepted: 7 November 2022

Published: 3 December 2022

References

1. A American Diabetes. 6 glycemic targets: standards of medical care in diabetes-2020. *Diabetes Care*. 2020;43:566–76.
2. Hoffman RP, Dye AS, Huang H, Bauer JA. Glycemic variability predicts inflammation in adolescents with type 1 diabetes. *J Pediatr Endocrinol Metab*. 2016;29:1129–33.
3. Rodrigues R, de Medeiros LA, Cunha LM, Garrote-Filho MDS, Bernardino Neto M, Jorge PT, Resende ES, Penha-Silva N. Correlations of the glycemic variability with oxidative stress and erythrocytes membrane stability in patients with type 1 diabetes under intensive treatment. *Diabetes Res Clin Pract*. 2018;144:153–60.
4. Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. *J Am Coll Cardiol*. 2018;71:339–51.
5. Olczuk D, Priefer R. A history of continuous glucose monitors (CGMs) in self-monitoring of diabetes mellitus. *Diabetes Metab Syndr*. 2018;12:181–7.
6. Lu M, Zuo Y, Guo J, Wen X, Kang Y. Continuous glucose monitoring system can improve the quality of glucose control and glucose variability compared with point-of-care measurement in critically ill patients: a randomized controlled trial. *Medicine*. 2018;97:e12138.
7. Krinsley JS, Chase JG, Gunst J, Martensson J, Schultz MJ, Taccone FS, Wernerman J, Bohe J, De Block C, Desai T, et al. Continuous glucose monitoring in the ICU: clinical considerations and consensus. *Crit Care*. 2017;21:197.
8. Schmidt S, Christensen MB, Serifovski N, Damm-Frydenberg C, Jensen JB, Floyel T, Storling J, Ranjan A, Norgaard K. Low versus high carbohydrate diet in type 1 diabetes: A 12-week randomized open-label crossover study. *Diabetes Obes Metab*. 2019;21:1680–8.
9. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, Yancy WS Jr, Brinkworth GD. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. *Am J Clin Nutr*. 2015;102:780–90.
10. Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. *Am J Clin Nutr*. 2013;97:505–16.
11. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metab*. 2018;27:740–56.
12. Marso SP, Daniels GH, Brown-Frandens K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311–22.
13. Bajaj HS, Venn K, Ye C, Patrick A, Kalra S, Khandwala H, Aslam N, Twum-Barima D, Aronson R. Lowest glucose variability and hypoglycemia are observed with the combination of a glp-1 receptor agonist and basal insulin (VARIATION study). *Diabetes Care*. 2017;40:194–200.
14. Meneghini LF. Insulin therapy for type 2 diabetes. *Endocrine*. 2013;43:529–34.
15. Schmelzeisen-Redeker G, Schoemaker M, Kirchsteiger H, Freckmann G, Heinemann L, Del Re L. Time delay of CGM sensors: relevance, causes, and countermeasures. *J Diabetes Sci Technol*. 2015;9:1006–15.
16. Aijan R, Slattery D, Wright E. Continuous glucose monitoring: a brief review for primary care practitioners. *Adv Ther*. 2019;36:579–96.
17. Wright LA, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. *Diabetes Technol Ther*. 2017;19:516–26.
18. Ugi S, Maegawa H, Morino K, Nishio Y, Sato T, Okada S, Kikkawa Y, Watanabe T, Nakajima H, Kashiwagi A. Evaluation of a novel glucose area under the curve (AUC) monitoring system: comparison with the AUC by continuous glucose monitoring. *Diabetes Metab J*. 2016;40:326–33.
19. Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. *Diabetes Technol Ther*. 2011;13:921–8.
20. Brown E, Cuthbertson DJ, Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. *Peptides*. 2018;100:61–7.
21. Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. *JAMA*. 2014;311:2315–25.
22. Abdalla MM. Central and peripheral control of food intake. *Endocr Regul*. 2017;51:52–70.
23. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. *Diabetes Obes Metab*. 2011;13:1008–19.
24. Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: what can be done? *Diabetes Obes Metab*. 2017;19:1655–68.
25. Salkind SJ, Huizenga R, Fonda SJ, Walker MS, Vigersky RA. Glycemic variability in nondiabetic morbidly obese persons: results of an observational study and review of the literature. *J Diabetes Sci Technol*. 2014;8:1042–7.
26. Ladenheim EE. Liraglutide and obesity: a review of the data so far. *Drug Des Devel Ther*. 2015;9:1867–75.
27. Mehta A, Marso SP, Neeland JJ. Liraglutide for weight management: a critical review of the evidence. *Obes Sci Pract*. 2017;3:3–14.
28. Gin H, Rigalleau V, Perlemonne C. Insulin therapy and body weight, body composition and muscular strength in patients with type 2 diabetes mellitus. *J Nutr Metab*. 2010. <https://doi.org/10.1155/2010/340570>.
29. Carris NW, Taylor JR, Gums JG. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. *Drugs*. 2014;74:2141–52.
30. Thomsen MN, Skytte MJ, Astrup A, Deacon CF, Holst JJ, Madsbad S, Krarup T, Haugaard SB, Samkani A. The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: a randomised controlled study. *Clin Nutr ESPEN*. 2020;39:46–52.
31. Alish CJ, Garvey WT, Maki KC, Sacks GS, Husted DS, Hegazi RA, Mustad VA. A diabetes-specific enteral formula improves glycemic variability in patients with type 2 diabetes. *Diabetes Technol Ther*. 2010;12:419–25.
32. Mori Y, Ohta T, Yokoyama J, Utsunomiya K. Effects of low-carbohydrate/high-monounsaturated fatty acid liquid diets on diurnal glucose variability and insulin dose in type 2 diabetes patients on tube feeding who require insulin therapy. *Diabetes Technol Ther*. 2013;15:762–7.
33. Sofizadeh S, Imberg H, Olafsdottir AF, Ekelund M, Dahlqvist S, Hirsch I, Filipsson K, Ahren B, Sjoberg S, Tuomilehto J, Lind M. Effect of liraglutide on times in glycaemic ranges as assessed by CGM for type 2 diabetes patients treated with multiple daily insulin injections. *Diabetes Ther*. 2019;10:2115–30.
34. Wang H, Zhou Y, Wang Y, Cai T, Hu Y, Jing T, Ding B, Su X, Li H, Ma J. Basal insulin reduces glucose variability and hypoglycaemia compared to pre-mixed insulin in type 2 diabetes patients: a study based on continuous glucose monitoring systems. *Front Endocrinol*. 2022;13:791439.
35. Tong CV, Mohd Noor N, Mohamad M. Glycemic Variability among Older Adults with Type 2 Diabetes. *J Diabetes Metab*. 2016. <https://doi.org/10.4172/2155-6156.1000652>.
36. Gude F, Diaz-Vidal P, Rua-Perez C, Alonso-Sampedro M, Fernandez-Merino C, Rey-Garcia J, Cadarso-Suarez C, Pazos-Couselo M, Garcia-Lopez JM, Gonzalez-Quintela A. Glycemic variability and its association with demographics and lifestyles in a general adult population. *J Diabetes Sci Technol*. 2017;11:780–90.
37. Murata GH, Duckworth WC, Shah JH, Wendel CS, Hoffman RM. Sources of glucose variability in insulin-treated type 2 diabetes: the diabetes outcomes in veterans study (DOVES). *Clin Endocrinol (Oxf)*. 2004;60:451–6.
38. Noyes JD, Soto-Pedre E, Donnelly LA, Pearson ER. Characteristics of people with high visit-to-visit glycaemic variability in type 2 diabetes. *Diabet Med*. 2018;35:262–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.